Expression of neutralizing recombinant human antibodies against varicella zoster virus for use as a potential prophylactic

Hybridoma

Volumn 19, Issue 2, 2000, Pages 143-149

  Lloyd Evans, P ^a   Gilmour, J E M ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY;

ARTICLE; INFECTION PREVENTION; ISOELECTRIC POINT; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; CAPSID; CELL LINE; CHICKENPOX; COMPLEMENT C1Q; GLYCOSYLATION; HERPESVIRUS 3, HUMAN; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN VARIABLE REGION; ISOELECTRIC POINT; MOLECULAR WEIGHT; PLAQUE ASSAY; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

DNA VIRUSES; HUMAN HERPESVIRUS 3;

EID: 0034129496     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/02724570050031185     Document Type: Article

References (37)

1. 1. Balfour HH, Kelly JM, Suarez CS, et al.: Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990;116: 633-639.
2. 2. Wilson A, Sharp M, Koropchak CM, Ting SF, and Arvin AM: Subclinical Varicella Zoster virus virema, Herpes Zoster, and T-lymphocyte immunity to Varicella Zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126.
3. 3. Zaia JA, Levin MJ, Preblud SR, Lesczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, and LeGore J: Evaluation of varicella-zoster immune globin; protection of immunosuppressed children afterhousehold exposure to varicella. J Infect Dis 1983;147: 737-743.
4. 4. Levin MJ, Nelson WL, Preblud SR, and Zaia JA: In: Clinical Use of Intravenous Immunoglobulins. Nydegger A (Ed.). Academic Press, London, 1986, pp. 124-158.
5. 5. Spear PG. Entry of alphaherpesviruses into cells. Sem Virol 1993;4: 167-180.
6. 6. Rodriguez JE, Moninger T, and Grose C: Entry and egress of Varicella Zoster virus blocked by the same anti-gH monoclonal Antibody. Virology 1993;196:840-844.
7. 7. Zhu Z, Gershon MD, Ambron R, Gabel C, and Gershon AA: Infection of cells by Varicella Zoster virus: Inhibition of viral entry by mannose 6-phosphate and heparin. PNAS (USA) 1995;92: 3546-3550.
8. 8. Cohen JI, and Straus SE: Varicella-zoster virus and its replication. In: Fields of Virology. 3rd ed. Fields BN, Knipe DM, and Howley PM (Eds.). Raven Publishers, NY, 1996, pp. 2525-2545.
9. 9. Davidson AJ, and Scott JE: The complete sequence of Varicella Zoster virus. J Gen Virol 1986;67:1759-1816.
10. 10. Ellis RW, Keller PM, Lowe RS, and Zivin RA: Use of a bacterial expression vector to map the Varicella Zoster virus major glycoprotein gene, gC. J Virol 1985;53:81-88.
11. 11. Keller PM, Davidson AJ, Lowe R, et al.: Identification and structure of the gene encoding gpII, a major glycoprotein of Varicella Zoster virus. Virology 1986;152:181-191.
12. 12. Keller PM, Davidson AJ, Lowe R, et al.: Identification and sequence of the gene encoding gpIII, a major glycoprotein of Varicella Zoster virus. Virology 1987;157:526-533.
13. 13. Olson JK, Bishop GA, and Grose C: Varicella-Zoster Fc receptor gE glycoprotein: Serine/Threonine and Tyrosine phosphorylation of monomeric and dimeric forms. J Virol 1997;71:110-119.
14. 14. Davidson AJ, Edson C, Ellis RW, et al.: A new common nomenclature for the glycoprotein genes of Varicella Zoster virus and their glycosylated products. J Virol 1986;57:1195-1197.
15. 15. Edson CM, Hosler BA, Poodry CA, et al.: Varicella Zoster virus envelope glycoproteins: Biochemical characterisation and identification in clinical material. Virology 1985;145:62-71.
16. 16. Forghani B, Dupuis KW, and Schmidt N: Varicella-Zoster viral glycoproteins analyzed by monoclonal antibodies. J Virol 1984;52:55-62.
17. 17. Wu L, and Forghani B: Characterisation of neutralizing domains on Varicella zoster virus glycoprotein E defined by monoclonal antibodies. Arch Virol 1997;142:349-362.
18. 18. Harper DR, Gilbert RL, and Jeffries DJ: Molecular biology of Varicella-zoster virus. J Infect 1998;36(suppl):1-10.
19. 19. Kabat EA, We TT, Perry HM, Gottesman KS, and Foeller C: Sequences of proteins of immunological interest. 5th ed. U.S. Department of Health and Human Services, 1991.
20. 20. Bebbington CR, Renner G, Thomson S, et al.: High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable marker. Biotechnology 1992;10:169-175.
21. 21. Laemmli U. Cleavage of structural proteins during the assembly of the head of a bacteriophage T4. Nature 1970;227:680-684.
22. 22. Horgan C, Brown K, and Pincus SH: Alteration in H chain V regions affect complement activation by chimeric antibodies. J Immunol 1990;145:2527-2532.
23. 23. Harper DR, Kangro HO, and Heath RB: Serological responses in Varicella and Zoster assayed by immunoblotting. J Med Virol 1988;25:387-398.
24. 24. Harper DR, Mathieu N, and Mullarkey J: High titre, cryostable cell-free Varicella zoster virus. Arch Virol 1998;143:1163-1170.
25. 25. Foung SKH, Perkins S, Koropchak C, et al.: Human monoclonal antibodies neutralising Varicell zoster virus. J Infect Dis 1985;2:280-285.
26. 26. Sugano T, Matsumo Y, Miyamoto C, and Masuho Y: Hybridoma producing human monoclonal antibodies against Varicella zoster virus. Eur J Immunol 1987;17:359-364.
27. 27. Nakatani T, Nomura N, Horigome K, et al.: Functional expression of human monoclonal antibody genes directed against Pseudonomal ExotoxinA in mouse myeloma cells. Biotechnology 1989;7:805-810.
28. 28. Tempest PR, Bremner P, Lambert M, et al.: Reshaping a human monoclonal antibody to inhibit human Respiratory Syncytial virus infection in vivo. Biotechnology 1991;9:265-271.
29. 29. Peakman TC, Worden J, Harris RH, et al.: Comparison of expression of a humanized monoclonal antibody in mouse NS0 myeloma cells and Chinese hamster ovary cells. Hum Antibod Hybridomas 1994;5:65-74.
30. 30. Brunell PA, Novelli VM, Keller PM, and Ellis RW: Antibodies to the three major glycoproteins of Varicella-Zoster virus: Search for the relevant host immune response. J Infect Dis 1987;156:430-435.
31. 31. Montano RF, and Romano EL: Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the galα1-3gal epitope. Hum Antibod Hybridomas 1994;5:152-162.
32. 32. Pumphrey RSH. The Human IgG Subclasses. Shakib F (Ed.). Pergamon Press, Oxford, 1990, p. 1-3.
33. 33. Junker AK, and Tilley P: Varicella Zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. J Med Virol 1994;43:19-24.
34. 34. D'Souza MP, Livnat D, Bradac JA, and Bridges SH: Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralisation assays: Criteria for selecting candidate antibodies for clinical trials. J Infect Dis 1997;175:1056-1062.
35. 35. Straus SE, Hay J, Smith H, and Owens J: Genome differences among Varicella Zoster virus isolates. J Gen Virol 1983;64:1031-1041.
36. 36. Hawrami K, Breuer J: Analysis of United Kingdom wild-type strains of Varicella Zoster virus: Differentation from the Oka vaccine strain. J Med Virol 1997;53:60-62.
37. 37. Santos RA, Padilla JA, Hatfield C, and Grose C: Antigenic variation of Varicella Zoster virus Fc receptor gE; Loss of a major B cell epitope in the ectodomain. Virology 1998;249:21-31.